Q3 2024 Earnings Estimate for AnaptysBio, Inc. (NASDAQ:ANAB) Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at HC Wainwright lifted their Q3 2024 EPS estimates for AnaptysBio in a research report issued to clients and investors on Wednesday, August 14th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($1.57) per share for the quarter, up from their previous estimate of ($1.67). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.32) per share. HC Wainwright also issued estimates for AnaptysBio’s Q4 2024 earnings at ($1.78) EPS, FY2024 earnings at ($6.70) EPS, FY2025 earnings at ($8.47) EPS, FY2026 earnings at ($11.13) EPS, FY2027 earnings at ($10.32) EPS and FY2028 earnings at ($9.21) EPS.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million.

Several other research firms have also recently commented on ANAB. Truist Financial raised their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of AnaptysBio in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.30.

AnaptysBio Stock Up 4.8 %

Shares of NASDAQ:ANAB opened at $34.00 on Friday. The company has a market cap of $928.85 million, a price-to-earnings ratio of -5.54 and a beta of -0.25. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $41.31. The firm’s 50-day simple moving average is $29.55 and its 200-day simple moving average is $25.63.

Hedge Funds Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. Algert Global LLC raised its holdings in AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 1,078 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the last quarter. Susquehanna Fundamental Investments LLC grew its position in shares of AnaptysBio by 32.9% in the second quarter. Susquehanna Fundamental Investments LLC now owns 72,060 shares of the biotechnology company’s stock valued at $1,806,000 after purchasing an additional 17,855 shares during the period. The Manufacturers Life Insurance Company increased its stake in AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock valued at $634,000 after purchasing an additional 8,418 shares during the last quarter. Finally, Alpha DNA Investment Management LLC purchased a new position in AnaptysBio during the second quarter worth about $399,000.

Insiders Place Their Bets

In other news, Director Hollings Renton sold 1,950 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $23.16, for a total transaction of $45,162.00. Following the completion of the transaction, the director now directly owns 1,950 shares of the company’s stock, valued at approximately $45,162. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Hollings Renton sold 1,950 shares of AnaptysBio stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total transaction of $45,162.00. Following the completion of the sale, the director now owns 1,950 shares in the company, valued at approximately $45,162. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now directly owns 7,794,996 shares in the company, valued at approximately $284,517,354. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 16,900 shares of company stock worth $484,824. Insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.